Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

The PROTAC (proteolysis-targeting chimera) ARV-825 recruits bromodomain and extraterminal (BET) proteins to the E3 ubiquitin ligase cereblon, leading to degradation of BET proteins, including BRD4. Whereas the BET-protein inhibitor (BETi) OTX015 caused accumulation of BRD4, treatment with equimolar...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leukemia
Autori principali: Saenz, Dyana T., Fiskus, Warren, Qian, Yimin, Manshouri, Taghi, Rajapakshe, Kimal, Raina, Kanak, Coleman, Kevin G., Crew, Andrew P., Shen, Angela, Mill, Christopher P., Sun, Baohua, Qiu, Peng, Kadia, Tapan M., Pemmaraju, Naveen, DiNardo, Courtney, Kim, Mi-Sun, Nowak, Agnieszka J., Coarfa, Cristian, Crews, Craig M., Verstovsek, Srdan, Bhalla, Kapil N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5537055/
https://ncbi.nlm.nih.gov/pubmed/28042144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.393
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi